04:46:50 PM

CGTX Stock News

CGTX - Cognition Therapeutics Inc

06/23/22 7:30 AM

Nasdaq : CGTX

clinical triallow float

Cognition Therapeutics Doses First Patient with Dementia with Lewy Bodies in Phase 2 Clinical Study of CT1812

Cognition Therapeutics , Inc. (Nasdaq: CGTX) today announced that the first patient has

RHEA-AI

positive

06/08/22 7:30 AM

Nasdaq : CGTX

low float

Cognition Therapeutics Announces Presentation at the Upcoming JMP Securities Life Sciences Conference

Cognition Therapeutics, Inc. (Nasdaq: CGTX) announced that the company will participate in the JMP Securities Life Sciences Conference on June 16th. Lisa Ricciardi, Cognition’s president and CEO will be presenting an update on the company's

RHEA-AI

neutral

06/02/22 4:01 PM

Nasdaq : CGTX

conferenceslow float

Cognition Therapeutics to Host Virtual KOL Symposium on Dry Age-related Macular Degeneration and the Potential for Sigma-2 Modulation

Cognition Therapeutics, Inc. (Nasdaq: CGTX), announced plans to hold a virtual KOL symposium on June 9, 2022, from 10:00 - 11:30 a.m. ET to discuss dry age-related macular degeneration (dry AMD). Cognition

RHEA-AI

neutral

05/13/22 7:30 AM

Nasdaq : CGTX

conferenceslow float

Cognition Therapeutics to Participate in H.C. Wainwright Global Investment Conference

Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that Lisa

RHEA-AI

neutral

05/11/22 7:00 AM

Nasdaq : CGTX

earningslow float

Cognition Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Update

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a

RHEA-AI

very positive

05/04/22 5:54 PM

Nasdaq : CGTX

conferencesearningslow float

CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously stated.

RHEA-AI

neutral

05/04/22 4:01 PM

Nasdaq : CGTX

conferencesearningslow float

Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022

Cognition Therapeutics, Inc. (NASDAQ: CGTX), a clinical-stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina (the “Company” or “Cognition”), today announced that it

RHEA-AI

neutral

05/03/22 8:00 AM

Nasdaq : CGTX

low float

Cognition Therapeutics Presented Preclinical Findings Showing that Sigma-2 Receptor Modulators Rescue Trafficking Deficits in Retinal Pigment Epithelial Cells in Model of Dry AMD

Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing therapies that treat age-related degenerative diseases of the central nervous system and retina, presented a poster today at the annual meeting of The

RHEA-AI

negative

04/25/22 4:01 PM

Nasdaq : CGTX

conferencesclinical triallow float

Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration

Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The

RHEA-AI

neutral

04/25/22 8:00 AM

Nasdaq : CGTX

low float

Cognition Therapeutics Announces Participation in B. Riley Securities 2022 Virtual Neuro & Ophthalmology Conference

Cognition Therapeutics, Inc. (Nasdaq: CGTX), a clinical stage neuroscience company developing drugs to treat age-related degenerative diseases of the central nervous system and retina, today announced that members of its management team will

RHEA-AI

neutral

1 2 3 Next